Divya Choudhary*a,
S. N. Naika,
Vidushi Tyagibc,
Anirban Palbc and
P. Hariprasadd
aSupercritical Extraction Laboratory, Centre, for Rural Development and Technology, Indian Institute of Technology Delhi, New Delhi-110016, India. E-mail: divyabt14@gmail.com; naiksn@gmail.com; Tel: +91 7303196165
bBioprospection and Product Development Division, Central Institute of Medicinal and Aromatic Plants (CSIR-CIMAP), Lucknow 226015, India. E-mail: itishatyagi2@gmail.com; drapaul@gmail.com
cAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, India
dEnvironmental Biotechnology Laboratory, Centre for Rural Development and Technology, Indian Institute of Technology Delhi, New Delhi 110016, India. E-mail: phimprovement.iitd@gmail.com
First published on 1st July 2025
Asparagus racemosus, commonly known as Shatavari, is a traditional Ayurvedic medicinal plant widely recognized for its broad spectrum of health-promoting properties, including antioxidant, anti-inflammatory, and adaptogenic activities. In recent years, fermentation has emerged as a powerful tool to enhance the bioavailability, therapeutic efficacy, and functional potential of such medicinal herbs. This study focuses on the development and toxicological evaluation of a Shatavari-based Low Alcohol Nutra-Beverage (SLANB), which is formulated through a controlled fermentation process to retain and possibly enhance its bioactive components. To ensure the safe consumption of SLANB as a functional food and potential therapeutic product, a comprehensive toxicological assessment was conducted. Metabolite profiling was performed using Liquid Chromatography-Mass Spectrometry (LC-MS), which led to the identification of ten major bioactive compounds that contribute to SLANB's health benefits. Additionally, Gas Chromatography-Mass Spectrometry (GC-MS) was employed to characterize volatile compounds, including key aroma constituents and ethanol content, present in the beverage after 28 days of fermentation. For safety evaluation, both acute and subacute toxicity studies were performed using Swiss albino mice as the animal model. In the acute toxicity study, SLANB was administered orally at a dose of 1.5 ml per 100 grams of body weight. The animals were closely observed for 7 days to monitor any signs of toxicity, behavioral changes, or mortality. No adverse effects or fatalities were observed during this period. Furthermore, a 28 days subacute toxicity study was carried out in which mice were divided into groups and administered SLANB orally at three different dose levels. Throughout the study period, the animals were monitored for changes in physiological parameters, including body weight, food and water intake, organ weight, and behavioral patterns. No abnormalities or signs of toxicity were noted in any of the treated groups, indicating that SLANB is well-tolerated. The absence of toxicological effects in both acute and subacute studies confirms the safety of SLANB for consumption. These findings strongly support its application as a safe nutraceutical beverage with potential utility in functional food and medicinal formulations. This research contributes valuable insights into the development of plant-based fermented functional beverages with health-promoting properties.
Sustainability spotlightThe developed Shatavari-based low-alcoholic Nutra-beverage (SLANB) promotes sustainable health solutions by utilizing Asparagus racemosus, a medicinal plant known for its antioxidant, anti-inflammatory, and adaptogenic properties. Fermentation significantly enhanced the bioavailability and functional potential of its key bioactive compounds. LC-MS analysis confirmed the presence of 10 distinct bioactive metabolites essential for health benefits, while GC-MS profiling revealed natural aroma and ethanol compounds after 28 days of fermentation. Toxicological evaluations demonstrated proven safety: an acute toxicity study using a 1.5 ml/100 g BW dose in mice showed no mortality or adverse effects over 14 days, and a 28 days subacute study across three dose levels confirmed no physiological toxicity. This eco-friendly innovation supports the development of a safe, functional nutraceutical beverage and validates SLANB as a non-toxic, plant-based formulation with potential applications in medicinal and wellness-oriented food systems. |
Shatavari is known for its inclusion in nutrient-enriched functional beverages due to its wealth of secondary metabolites, including steroidal saponins, flavonoids, polyphenols, and alkaloids, which are associated with numerous health benefits such as antioxidant, anti-inflammatory, adaptogenic, and immunomodulatory effects.3,4 The conversion of Shatavari roots into shelf-stable and value-added formulations not only prolongs their usability but also enhances the economic returns for producers and industries focused on functional and nutraceutical food products. One of the sustainable and efficient approaches to achieving this transformation is bioprocessing through fermentation, which has been increasingly recognized for its ability to improve nutritional quality, safety, and organoleptic properties of food products.5 Fermentation facilitates the breakdown of complex phytochemicals into bioavailable forms, potentially enhancing the pharmacological efficacy of herbal components.
Numerous studies have highlighted the pharmacological significance of Shatavari, attributing to it a broad spectrum of therapeutic properties including aphrodisiac, galactagogue, diuretic, antispasmodic, and adaptogenic effects.6 These therapeutic potentials have led to its inclusion in more than 64 traditional Ayurvedic formulations such as Shatavari Kalpa, Phalaghrita, and Vishnu Taila, which are employed for the management of reproductive, digestive, and nervous system disorders in both men and women.
Artificial Neural Network (ANN) coupled with Genetic Algorithm (GA) was successfully utilized to model and optimize fermentation parameters for the development of a low-alcohol Shatavari-based Nutra-beverage. The ANN-GA model effectively predicted the fermentation outcomes, including ethanol yield and antioxidant activity, thus providing a computationally robust tool for process optimization. Specifically, the model predicted and experimental outcomes aligned closely, with ethanol yield reaching 3.21 g L−1 and antioxidant activity recorded at 421.47 μg L−1, indicating enhanced functional properties during fermentation.7 This demonstrates the potential of ANN-GA in improving biotechnological applications in the food and nutraceutical sectors.8
Despite the promising pharmacological attributes of Shatavari, safety concerns associated with herbal and alternative medicines have gained attention, particularly with growing evidence of toxicity and adverse effects in some Ayurvedic formulations. Such safety risks are often linked to contamination, adulteration, or incorrect dosage, emphasizing the importance of rigorous toxicological evaluation.9,10 Currently, limited data exist regarding the acute and sub-acute toxicity of Shatavari-based nutraceutical beverages, thereby necessitating systematic in vivo studies to evaluate their safety profiles before commercialization. Ensuring the toxicological safety of these preparations is critical for consumer health and regulatory compliance.
To address these concerns, our study includes acute and sub-acute toxicity assessments in animal models, alongside sensory evaluation protocols to determine consumer acceptance of the developed product.
For fermentation, Saccharomyces cerevisiae NCIM 2428 was cultured in YEPD medium and incubated at 150 rpm for 24 hours. The activated inoculum was transferred to sterile Shatavari juice (pH 3.4) in 3-L Erlenmeyer flasks. Sucrose was added to increase sugar content to 190 g L−1 (as glucose), and fermentation parameters such as temperature (28–35 °C), pH (4–6), and inoculum concentration (1–5%, v/v) were optimized according to experimental design.12
Fermentation was carried out under sterile conditions in a 3-L BioFlo/CelliGen 115 bioreactor with a working volume of 2 L and agitation set at 150 rpm. Upon completion, the fermented product was centrifuged at 4000 rpm for 10 minutes, and the resulting supernatant was stored at 20 °C in the dark for 90 days.13 The preparation process of the Shatavari-based low-alcohol Nutra-beverage is illustrated in Fig. 1.
Participants were advised to cleanse their palates with water between samples to ensure accurate evaluation and to clean their glasses. The sensory evaluation followed the method described.14 The overall experimental flow diagram of SLANB sample is depicted in Fig. 2, outlining the stages from formulation to consumer feedback. The hedonic scale test was conducted prior to the safety evaluation of the beverages and spanned from day 0 to day 28 of the experiment. Once the samples receiving the highest sensory scores—based on consumer preferences for taste and odor—were identified, the corresponding fermentation day was selected for further analysis. A toxicity study was subsequently performed on the beverage sample from this optimal day to evaluate its safety.
Attributes | Summary of sensory | |||
---|---|---|---|---|
Sample 1 (0th–7th day) | Sample 2 (7th–14th day) | Sample 3 (14th–21st day) | Sample 4 (21st–28th day) | |
Texture | 6 | 7 | 8 | 4 |
Aroma | 9 | 10 | 11 | 9 |
Taste | 13 | 15 | 16 | 10 |
Color | 15 | 17 | 18 | 18 |
Flavor | 10 | 14 | 15 | 13 |
Aftertaste | 14 | 15 | 16 | 12 |
The texture, aroma, taste, colour, flavour, and aftertaste of four distinct samples were evaluated, and their ratings are presented in Table 1. The results revealed that Sample 1 had a texture rating of 6, making it moderately likeable, while Sample 2 received a slightly higher rating of 7. Sample 3 achieved the highest texture rating of 8, indicating it was the most preferred among all samples. In contrast, Sample 4 received a lower rating of 4, suggesting it was the least liked.
In terms of aroma, Sample 3 was again the most favoured. Regarding taste, Sample 3 received the highest overall score of 16, making it the most satisfying in terms of flavour. Although Samples 1, 2, and 4 were acceptable, they did not surpass Sample 3 in any category.
The flavour and aftertaste of Sample 3 (14th–21st day of fermentation) were also well-received, though no other sample matched its high ratings. Similarly, in terms of colour, Sample 3 was considered the best overall. Fig. 3 presents a radar chart illustrating the sensory acceptability of the samples from the 0th to the 28th day of fermentation.
![]() | ||
Fig. 3 Sensory acceptability of 0th–28th days of fermentation, 0th–7th day (Sample 1); 7th–14th day (Sample 2); 14th–21st day (Sample 3); and 21st–28th day (sample 4). |
Compounds | Fermentation days | |||||
---|---|---|---|---|---|---|
Retention time | 0th day | 7th day | 14th day | 21st day | 28th day | |
Ether group | ||||||
Ethyl ether | 4.33 | 2.21 | 7.03 | 1.23 | 0.33 | nd |
![]() |
||||||
Alkane | ||||||
Pentane | 5.41 | 9.05 | 9.05 | nd | nd | nd |
Hexane | 5.90 | nd | nd | 10.69 | 4.77 | nd |
![]() |
||||||
Carboxylic group | ||||||
Ethyl acetate | 7.36 | nd | nd | nd | 31.26 | 27.05 |
Succinic acid | 4.34 | nd | nd | 5.48 | 7.54 | 6.08 |
Oxalic acid | 5.07 | nd | nd | 0.95 | 0.28 | nd |
Acetic acid | 7.02 | nd | nd | 0.04 | 0.07 | nd |
![]() |
||||||
Fatty acid | ||||||
2-Hydroxyoctanoic acid | 4.23 | nd | nd | nd | 31.91 | 23.05 |
![]() |
||||||
Ketones | ||||||
Acetoin | 12.36 | nd | 2.09 | 2.19 | 2.39 | nd |
![]() |
||||||
Alcohols | ||||||
Phenylethyl alcohol | 31.65 | nd | 0.50 | nd | nd | Nd |
Propargyl alcohol | 14.52 | nd | nd | 0.85 | nd | 0.10 |
1-Butanol | 12.59 | nd | 2.58 | nd | 32.61 | Nd |
During the fermentation process, the composition of volatile compounds varied over different days. Alcoholic compounds were notably detected on the 7th day of fermentation. Phenylethyl alcohol appeared with a peak area of 0.50 and a retention time of 31.65 minutes, but was not detected on subsequent days. Similarly, propargyl alcohol was detected on the 7th day with a peak area of 0.85 and a retention time of 14.52 minutes. 1-Butanol was observed at a retention time of 12.59 minutes on both the 7th and 21st days, with peak areas of 2.58 and 32.61, respectively. The ketone compound acetoin was identified with a retention time of 12.36 minutes. The corresponding chromatogram peaks are shown in ESI Fig. S1.†
GC-MS analysis revealed that the number and relative abundance of volatile compounds were influenced by storage duration. In the freshly fermented Shatavari beverage (Day 7, D7), 11 volatile components were identified, comprising a total area percentage of 21.25%. During storage at 32 °C, the number of volatiles varied: 12 components on Day 14 (D14), 10 on Day 21 (D21), and 8 on Day 28 (D28). Interestingly, the total area percentage of volatile compounds increased to 20.57%, 111.16%, and 56.28% on D14, D21, and D28, respectively.
These findings suggest that volatile compounds peak around the 14th day of fermentation, contributing to enhanced aroma. After the 21st day, the levels begin to decline, likely due to the release of CO2, which may reduce the concentration of aroma-active compounds. The fruity and floral aroma in fermented products such as wine is typically associated with esters, which are synthesized through esterification of alcohols with fatty acids, or via alcohol acetyltransferase-mediated reactions involving acetyl-CoA and higher alcohols.20
While the fermented Shatavari beverage contained fewer esters than the fresh beverage, ester content increased after 7–14 days at 32 °C compared to day 0. Alcohols in the beverage are primarily derived from alcoholic fermentation, amino acid metabolism, and the oxidation of linolenic acid degradation products,21 all of which contribute desirable aromas.22 The alcohols detected during storage included phenylethyl alcohol, propargyl alcohol, and 1-butanol (Table 2). The highest total alcohol area percentage (32.61%) was observed on the 21st day, while lower values were recorded on the 7th and 14th days, at 3.18% and 0.85%, respectively. The higher alcohol content in stored fermented Shatavari beverages, compared to freshly fermented ones, could be attributed to continued yeast activity at elevated temperatures, which promotes the conversion of residual sugars into alcohol. These alcohols impart fruity, floral, and characteristic alcoholic aromas to the beverage.
Acids and ketones serve as both primary metabolites and precursors to aromatic compounds. Secondary metabolites such as esters and lactones are formed through the interaction of volatiles—including alcohols and fatty acids—during fermentation.23 Although present in small amounts, these additional volatile compounds may play a significant role in the aroma and flavor profile of the fermented Shatavari beverage.
Compounds name | Formula | m/z | Retention time/relative abundance (%) | Pharmacological importance/literature references | ||||
---|---|---|---|---|---|---|---|---|
0th day | 7th day | 14th day | 21st day | 28th day | ||||
a nd = not detected; m/z = mass-to-charge ratio; retention time given in minutes; relative abundance presented in percentage (%); pharmacological importance reported as antioxidant or immunomodulatory based on existing literature; detected compounds were tentatively identified using LC-MS/MS. | ||||||||
Chalconaringenin 2′-rhamnosyl-(1->4)-glucoside | C27H32O14 | 580.2 | nd | nd | 10.89 (30%) | nd | nd | Antioxidant |
Shatavarin I | C51H86O23 | 1066.5 | nd | 11.13 (25%) | 10.69 (80%) | 10.70 (40%) | 10.70 (40%) | Antioxidant (3) |
Shatavarin VIII | C50H82O22 | 1034.5 | nd | 13.83 (73%) | 13.85 (87%) | nd | 13.84 (72%) | Antioxidant (3) |
Shatavarin V | C45H74O17 | 886.4 | nd | 17.32 (75%) | 17.32 (80%) | 17.32 (85%) | 17.32 (80%) | Immunomodulatory (6) |
Shatavarin IX | C45H74O18 | 902.4 | 17.28 (37%) | 17.28 (40%) | 17.28 (45%) | 17.28 (45%) | 17.28 (32%) | Immunomodulatory (6) |
The composition of the colony will change accordingly,24 leading to changes in mycelium color, colony vitality, texture characteristics of the product, sensory acceptance, and product quality. The longer the fermentation time, the darker the color of the FAR fermented Shatavari beverage, due to the oxidation of polyphenol and flavonoid compounds, resulting in color browning. Other factors, such as light and temperature, might contribute to the degradation of phenolic compounds.25 When these substances are oxidized, they form brown pigments that may eventually precipitate.26
The five signature compounds were identified by LC-ESI/MS (LC-MS) analysis using Waters Alliance e2695/HPLC-TQD Mass spectrometer instrument, namely Chalconaringenin 2′-rhamnosyl-(1->4)-glucoside, Shatavarin I, Shatavarin VIII, Shatavarin V, Shatavarin IX, Asparoside B, Quercetin, Lysyl-Asparagine compounds. To further investigate the effect of fermentation, representative metabolites were selected for relative abundance analysis in this study. The data from Table 3 regarding the relative abundance of specific compounds in the Shatavari-based nutra-beverage are refined as a Shatavarin VIII is observed to be present in relatively high abundance within the nutra-beverage formulation. Both Shatavarin I and Shatavarin V are found in equal abundance levels, suggesting a balanced presence of these saponins. Asparoside B emerges as the most abundant compound, highlighting its significant contribution to the beverage's composition. Conversely, the compound Chalconaringenin 2′-rhamnosyl-(1->4)-glucoside is noted for its low abundance in the formulation, all of which are shown in Fig. 4.
![]() | ||
Fig. 4 Untargeted compounds identified in the product on the 14th day of fermentation showing relative abundance and validation. |
Parameters | Control | Nutrabeverage |
---|---|---|
a Values are expressed as mean ± standard deviation (n = 6). SGOT: serum glutamate oxaloacetate transaminase; SGPT: serum glutamate pyruvate transaminase; ALP: alkaline phosphatase; RBC: red blood cells; WBC: white blood cells. No significant difference (p > 0.05) was observed between control and Nutra-beverage groups. | ||
Change in bd wt (g) | 3.79 ± 0.56 | 3.89 ± 0.42 |
Haemoglobin (g dl−1) | 17.92 ± 0.75 | 18.28 ± 1.31 |
RBC (million/mm3) | 6.02 ± 0.08 | 6.11 ± 0.13 |
WBC (×1000/mm3) | 6.81 ± 0.23 | 6.21 ± 0.85 |
SGOT (U l−1) | 51.38 ± 2.05 | 49.73 ± 2.10 |
SGPT (U l−1) | 30.05 ± 2.89 | 28.11 ± 2.76 |
ALP (U l−1) | 102.82 ± 16.58 | 111.07 ± 13.08 |
Creatinine (mg dl−1) | 0.80 ± 0.37 | 0.51 ± 0.23 |
Triglyceride (mg dl−1) | 122.07 ± 4.01 | 121.14 ± 6.38 |
Cholesterol (mg dl−1) | 161.90 ± 4.74 | 158.18 ± 6.30 |
Bilirubin (mg dl−1) | 0.36 ± 0.03 | 0.30 ± 0.04 |
Moreover, no significant difference was observed in the mean values of absolute and relative weights of essential organs, including the kidney, liver, lung, heart, and spleen, in the treatment group compared to the control group (see Fig. 5).
![]() | ||
Fig. 5 Effect of Nutra-beverage as a single acute oral dose at 1.5 ml/100 g body weight on absolute and relative organ weight in mice (n = 6). |
Nutraceutical beverage at a single dose of 1.5 ml/100 g body weight did not induce any significant change in haematological parameters [RBC count, WBC count and Haemoglobin (Hb)] in either of the sex studied (Table 4). Creatinine, SGOT, SGPT, total cholesterol, triglycerides, bilirubin, and alkaline phosphatase did not vary significantly either.
Parameters | Control | 75 | 150 | 300 |
---|---|---|---|---|
a Values are expressed as mean ± standard deviation (SD), n = 6 animals per group. Control: received distilled water only. 75, 150, 300: received SLANB at doses of 75, 150, and 300 mg kg−1 body weight, respectively, for 28 days. No significant differences (p > 0.05) observed in most parameters 115 among treated groups compared to control, indicating no adverse effects. Negative change in body weight observed only at 300 mg kg−1. | ||||
Body weight (g) | 27.34 ± 1.04 | 27.41 ± 1.32 | 26.41 ± 2.23 | 22.14 ± 0.95 |
Change in bd wt (g) | 5.50 ± 1.52 | 6.81 ± 0.64 | 7.56 ± 1.39 | −2.12 ± 0.57 |
Haemoglobin (g dl−1) | 16.57 ± 0.59 | 16.22 ± 0.40 | 17.17 ± 0.44 | 19.3 ± 0.32 |
RBC (million/mm3) | 7.05 ± 0.14 | 7.02 ± 0.39 | 7.11 ± 0.05 | 6.84 ± 0.17 |
WBC (×1000/mm3) | 6.66 ± 0.19 | 6.20 ± 0.20 | 6.23 ± 0.16 | 6.63 ± 0.26 |
SGOT (U l−1) | 34.51 ± 2.72 | 39.46 ± 2.17 | 38.97 ± 2.37 | 21.72 ± 1.30 |
SGPT (U l−1) | 22.98 ± 4.74 | 22.01 ± 1.45 | 29.67 ± 2.91 | 23.17 ± 3.27 |
ALP (U l−1) | 82.50 ± 9.67 | 84.03 ± 3.01 | 89.99 ± 6.31 | 72.88 ± 2.46 |
Creatinine (mg dl−1) | 0.72 ± 0.24 | 0.56 ± 0.10 | 0.67 ± 0.16 | 0.72 ± 0.12 |
Triglyceride (mg dl−1) | 161.90 ± 8.42 | 165.95 ± 15.89 | 163.81 ± 3.02 | 184.29 ± 4.67 |
Cholesterol (mg dl−1) | 127.23 ± 7.90 | 119.39 ± 4.07 | 117.65 ± 2.65 | 134.42 ± 7.31 |
Bilirubin (mg dl−1) | 0.14 ± 0.01 | 0.13 ± 0.01 | 0.20 ± 0.03 | 0.23 ± 0.02 |
Moreover, the absolute and relative organ weights of kidney, lung, heart, liver, and spleen in group 2, 3, and 4 was comparable to the control group (see Fig. 6). Additionally, the haematological parameters including RBC count, WBC count and Haemoglobin (Hb) also remained within normal ranges across all three dosage of 0.375 ml, 0.75 ml and 1.5 ml/100 g body weight. Furthermore, there was no significant changes were observed in biochemical parameters such as serum creatinine, SGOT, SGPT, total cholesterol, triglycerides, bilirubin, and Alkaline phosphatase (ALP).
![]() | ||
Fig. 6 Effect of Nutra-beverage as a single acute oral dose at 0.375 ml, 0.75 ml, and 1.5 ml g−1 body weight on absolute and relative organ weight in mice (n = 6). |
No one died or got sick throughout the experiment. At 0.375 ml and 0.75 ml/100 g of BW, acute and sub-acute testing showed no significant changes in body weight, however group 4 (1.5 ml/100 g of BW) showed a reduction compared to control. This impact could be due to the high antioxidant nature of nutraceutical beverage that helps in losing body weight. No alterations were noted in the assessment of vital organ weights, both absolutely and relatively. The hematological parameters exhibited negligible alterations. SGOT, serum creatinine, total cholesterol, triglycerides, bilirubin, and ALP all showed no significant increases (Table 5). This is the first report on the safety profile of chemically characterized Nutraceutical beverage, an herbal formulation of much use in Ayurvedic Medicine. A parallel investigation with Bacopa monnieri leaf enriched extract at acute and sub-acute levels in Sprague-Dawley rats found that 500 mg kg−1 body weight for 14 days and 85, 210, and 500 mg kg−1 for 90 days were well tolerated.
However, there is no report on the toxicity profile of Nutraceutical beverage. We have used Nutraceutical beverage, which is chemically defined and chemical constituents for the safety profiling. Nutraceutical beverage did not affect morbidity and mortality in our investigation, including body weight, important organ weight, and main biochemical indicators. Our data indicate that a single oral dose of Nutraceutical beverage at 1.5 ml g−1 of body weight is well tolerated in both male and female Swiss albino mice, as well as doses of 0.375 ml, 0.75 ml, and 1.5 ml g−1 of body weight administered once daily for 28 days.
Similarly, the analysis of absolute organ weight demonstrated no significant variations between the control and beverage groups. This further confirms that the beverage does not interfere with the normal growth or development of individual organs, underscoring its non-toxic nature in terms of organ-specific impacts.
In terms of body weight, no significant differences were observed between the control and beverage groups, highlighting that the beverage had no detrimental effect on overall body growth or weight regulation. This outcome suggests that the beverage is metabolically neutral, with no apparent influence on weight gain or loss during the study period.
Overall, these findings collectively indicate the safety of the beverage, as evidenced by the absence of adverse effects on relative and absolute organ weights as well as body weight in comparison to the control group. This provides a strong basis for considering the beverage as a safe functional product for further development and consumption.
Footnote |
† Electronic supplementary information (ESI) available. See DOI: https://doi.org/10.1039/d5fb00109a |
This journal is © The Royal Society of Chemistry 2025 |